Terms: = Ovarian cancer AND CBFA2T3, ETO2, 863, ENSG00000129993, ZMYND4, MTGR2, MTG16 AND Treatment
8 results:
1. Efficacy of gemcitabine in combination with nanoparticle albumin-bound paclitaxel in the treatment of recurrent ovarian cancer: A retrospective single institution review.
Kase AM; Azzouqa AG; Kochuveettil S; Colon-Otero G
Cancer Med; 2023 Apr; 12(8):9434-9438. PubMed ID: 36806695
[TBL] [Abstract] [Full Text] [Related]
2. Incidence and risk of venous thromboembolism according to primary treatment in women with ovarian cancer: A retrospective cohort study.
Yuk JS; Lee B; Kim K; Kim MH; Seo YS; Hwang SO; Yoon SH; Kim YB
PLoS One; 2021; 16(4):e0250723. PubMed ID: 33909674
[TBL] [Abstract] [Full Text] [Related]
3. [Bioinformatics analysis of drug-resistant ceRNA in epithelial ovarian cancer].
Pan ZM; Tan FC; Chen CX; Zhang W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2021 Feb; 56(2):121-130. PubMed ID: 33631884
[No Abstract] [Full Text] [Related]
4. Assessment of diagnostic utility of multivariate diagnostic models in differential diagnosis of ovarian tumors.
HoraĆa A; Swiatly A; Lorek J; Kokot ZJ; Matysiak J; Nowak-Markwitz E
Ginekol Pol; 2018; 89(10):568-572. PubMed ID: 30393846
[TBL] [Abstract] [Full Text] [Related]
5. Postoperative chemotherapy had no prognostic effect on early-staged young ovarian cancer with unilateral resection.
Zhang X; Wang S; Zhao S; Sun Y; Yang G
Cancer Med; 2018 Nov; 7(11):5488-5496. PubMed ID: 30306725
[TBL] [Abstract] [Full Text] [Related]
6. Predictive Factors for Surgical Morbidities and Adjuvant Chemotherapy Delay for Advanced ovarian cancer Patients Treated by Primary Debulking Surgery or Interval Debulking Surgery.
Castro BGR; Dos Reis R; Cintra GF; Sousa MMA; Vieira MA; Andrade CEMDC
Int J Gynecol Cancer; 2018 Oct; 28(8):1520-1528. PubMed ID: 30036229
[TBL] [Abstract] [Full Text] [Related]
7. Survival Disparities by Hospital Volume Among American Women With Gynecologic cancers.
Seagle BL; Strohl AE; Dandapani M; Nieves-Neira W; Shahabi S
JCO Clin Cancer Inform; 2017 Nov; 1():1-15. PubMed ID: 30657373
[TBL] [Abstract] [Full Text] [Related]
8. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.
Oza AM; Tinker AV; Oaknin A; Shapira-Frommer R; McNeish IA; Swisher EM; Ray-Coquard I; Bell-McGuinn K; Coleman RL; O'Malley DM; Leary A; Chen LM; Provencher D; Ma L; Brenton JD; Konecny GE; Castro CM; Giordano H; Maloney L; Goble S; Lin KK; Sun J; Raponi M; Rolfe L; Kristeleit RS
Gynecol Oncol; 2017 Nov; 147(2):267-275. PubMed ID: 28882436
[TBL] [Abstract] [Full Text] [Related]